Galectin Therapeutics Inc. (GALT)
USD 2.02
(-4.72%)
USD 2.02
(-4.72%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.96 Million | -31.05 Million | -24.3 Million | -20.6 Million | -10.84 Million | -10.17 Million |
| Net Income | -41.06 Million | -38.77 Million | -30.52 Million | -23.46 Million | -13.29 Million | -13.9 Million |
| Depreciation & Amortization | 33 Thousand | 32 Thousand | 41 Thousand | 36 Thousand | 35 Thousand | - |
| Deferred income taxes | -2.67 Million | - | -138 Thousand | - | - | - |
| Stock-based compensation | 2.26 Million | 2.86 Million | 2.07 Million | 1.79 Million | 1.68 Million | 4.44 Million |
| Change in working capital | 4.67 Million | 4.96 Million | 3.75 Million | 942 Thousand | 641 Thousand | -1.07 Million |
| Other non-cash items | 3.8 Million | -147 Thousand | 489 Thousand | 87 Thousand | 87 Thousand | 348 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 40.03 Million | 10 Million | 36.81 Million | 263 Thousand | 50.07 Million | 15.37 Million |
| Debt repayment | -30 Million | -10 Million | -30 Million | - | - | - |
| Dividends payments | -120 Thousand | -97 Thousand | -171 Thousand | -137 Thousand | -394 Thousand | -915 Thousand |
| Common Stock Repurchased | 671 Thousand | 899 Thousand | -30 Million | - | - | - |
| Common Stock Issuance | 40.03 Million | 10 Million | 6.81 Million | 263 Thousand | 50.46 Million | 15.37 Million |
| Other Financing Activities | 10.03 Million | 9.19 Million | 90.17 Million | 137 Thousand | 50.46 Thousand | 15.37 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 2.67 Million | 4.24 Million | 3.68 Million | 2.53 Million | 997 Thousand | -1.09 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2 Million | 724 Thousand | 65 Thousand | -1.59 Million | -356 Thousand | 19 Thousand |
| Cash at beginning of period | 18.59 Million | 39.64 Million | 27.14 Million | 47.48 Million | 8.25 Million | 3.05 Million |
| Cash at end of period | 25.66 Million | 18.59 Million | 39.64 Million | 27.14 Million | 47.48 Million | 8.25 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 7.06 Million | -21.05 Million | 12.5 Million | -20.33 Million | 39.22 Million | 5.2 Million |
| Free Cash Flow | -32.96 Million | -31.05 Million | -24.3 Million | -20.6 Million | -10.84 Million | -10.17 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.37 Million | -11.48 Million | -9.99 Million | -41.06 Million | -10.42 Million | -9.11 Million |
| Depreciation & Amortization | 9000.00 | 9000.00 | 9000.00 | 33 Thousand | 8000.00 | -16 Thousand |
| Deferred income taxes | - | - | 4.56 Million | -2.67 Million | 490 Thousand | -490 Thousand |
| Stock-based compensation | 738 Thousand | 604 Thousand | 497 Thousand | 2.26 Million | 586 Thousand | 516 Thousand |
| Change in working capital | 3.15 Million | -2.3 Million | 4.93 Million | 4.67 Million | 1.51 Million | -898 Thousand |
| Other non-cash items | -1.01 Million | 4.99 Million | -4.7 Million | 3.8 Million | 192 Thousand | 169 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 10.37 Million | 10 Million | 10 Million | 40.03 Million | 10.03 Million | 10 Million |
| Debt repayment | -10 Million | -10 Million | -10 Million | -30 Million | - | -10 Million |
| Dividends payments | - | -72 Thousand | -120 Thousand | -120 Thousand | - | - |
| Common Stock Repurchased | - | 277 Thousand | 374 Thousand | 671 Thousand | - | - |
| Common Stock Issuance | 376 Thousand | - | 30 Million | 40.03 Million | 10.03 Million | - |
| Other Financing Activities | 376 Thousand | 9.79 Million | 29.77 Million | 10.03 Million | 10.03 Million | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.91 Million | -3.29 Million | 5.07 Million | 2.67 Million | 621 Thousand | -1.65 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.23 Million | 988 Thousand | -143 Thousand | 2 Million | 894 Thousand | 757 Thousand |
| Cash at beginning of period | 23.55 Million | 25.66 Million | 20.36 Million | 18.59 Million | 17.96 Million | 17.99 Million |
| Cash at end of period | 25.59 Million | 23.55 Million | 25.66 Million | 25.66 Million | 20.36 Million | 17.96 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 2.04 Million | -2.1 Million | 5.29 Million | 7.06 Million | 2.39 Million | -33 Thousand |
| Free Cash Flow | -8.33 Million | -12.1 Million | -4.7 Million | -32.96 Million | -7.63 Million | -9.83 Million |
CTRYY
EDD
INNPF
SMAWF
FSS
603396